Sanquin Reagents

• Sanquin Health Solutions (SHS), the commercial subsidiary of the Sanquin Blood Supply Foundation to sell its reagents branch to Gilde Healthcare, a specialized Dutch investment company in the healthcare sector
• Sanquin Reagents produces and sells blood group and immune reagents for diagnostic research and drug development to a global clients base consisting of international research labs, hospitals and diagnostic test equipment manufacturers. Its products meet the highest quality requirements and generated around €25 million in revenue in the past year
• With Gilde Healthcare, SHS has found a formidable and ambitious investor with an impressive track record deemed capable of facilitating and accelerating further upscaling and development of Sanquin Reagents
• The acquisition, which is still subject to customary approval under the Works Councils Act, is expected to be completed in the coming months
• This transaction marks the third carve-out transaction in the past two years in which Kempen & Co acted as a financial adviser to a leading healthcare organisation in the Benelux, following the sale of Galapagos’ CRO subsidiary Fidelta in 2021 and the spin-out of InnoSIGN (mRNA tests) out of Philips in March 2022

Sanquin Reagents is part of Sanquin Health Solutions and has been an active player in the field of laboratory diagnostics by developing, producing and supplying both conventional and innovative products for diagnostics for more than 40 years. Sanquin Reagents develops and produces reagents for blood grouping and specific plasma proteins (IgG subclasses, cytokines, CD monoclonals). These reagents are for in vitro diagnostic use or for research use only and with these products, Sanquin Reagents aims to enhance the health of people.

It is the mission of Sanquin Health Solutions to fully unlock and utilize the potential of blood and science for the benefit of patients. SHS is the parent company of Sanquin's private activities in the fields of diagnostics, in vitro reagents, technology innovation and science campus development. SHS also has a number of participating interests. SHS is 100% owned by the Sanquin Blood Supply Foundation. Proceeds from SHS's commercial activities benefit, among other things, its research activities, which are used to develop new drugs and treatment methods.

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Financial Adviser in the up to SEK 250 million non-dilutive financing by Mendus
• Joint Global Coordinator in the SEK 299 million Directed share issue via a club deal by BioInvent
• Sole Global Coordinator in the SEK 200m financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue by Abliva
• Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma 
• Co-Manager in the USD 700 million Capital Increase by argenx
• Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
• Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
• Co-Lead Manager in the USD 115 million Nasdaq Initial Public Offering by IO Biotech
• Lead manager in the USD 127 million Global Offering of Merus
• Joint Global Coordinator and Joint Bookrunner in the €31.5 million Euronext IPO by MaaT Pharma
• Co-Manager in the USD 460 million Capital Increase by Ascendis Pharma
• Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics